Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Innodata Inc (INOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Innodata Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Innodata Inc trades at $61.54 (market cap $2.05B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 14.4× Innodata Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | INOD | |
|---|---|---|
Market Cap | $29.60B | $2.05B |
Sector | Health | Technology |
52-Week High | $491.22 | $121.50 |
52-Week Low | $205.48 | $34.45 |
Enterprise Value | $27.56B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
INOD trades at $61.47, down 1.21% today, but maintains strong technical support at $60-$62 levels with bullish oscillators and mixed moving averages. The company demonstrates robust fundamental performance with 58% year-over-year revenue growth in Q2 2026, beating earnings estimates for three consecutive quarters, and expanding profit margins to 14.66%. Recent AI-driven business developments and strong analyst coverage support the positive momentum.
INOD presents a compelling growth opportunity with accelerating AI services demand and consistent earnings outperformance, though premium valuation metrics (P/E 48.6, P/S 6.8) warrant caution. Key risks include customer concentration and competitive pressures in the rapidly evolving AI sector. Analyst consensus remains bullish with a $130 price target representing 111% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →
